negative
Recently
Key Gardasil slowdown drags Merck full-year outlook below estimates
K-driven concerns emerged after Merck’s full-year forecast missed estimates, with slowing Gardasil sales offsetting strength in its oncology drug portfolio.
Keeping investors cautious, Merck issued a full year forecast that fell short of market expectations as weaker demand for its Gardasil vaccine weighed on growth projections. The company flagged softer sales momentum in key international markets and rising competition pressures. While its oncology portfolio remained stable, analysts said Gardasil headwinds could limit near-term earnings visibility and temper sentiment around Merck’s revenue growth trajectory.